Sotorasib (Lumakras)
Other Medications · Approved since 2021
Description
Sotorasib is a KRAS G12C inhibitor specifically designed to target colorectal cancers harboring the KRAS p.G12C mutation. This targeted therapy is used in combination with other agents like panitumumab and FOLFIRI chemotherapy for patients with metastatic colorectal cancer containing this specific mutation. Sotorasib represents a breakthrough in treating KRAS-mutated colorectal cancers, which were previously considered "undruggable" due to the difficulty in targeting mutant KRAS proteins.
Mechanism of Action
Sotorasib works by covalently binding to the KRAS G12C mutant protein in its inactive GDP-bound state, effectively locking it in the "off" position. This prevents the mutant KRAS protein from activating downstream signaling pathways that promote cancer cell growth and survival, including the MAPK and PI3K/AKT pathways.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Lumakras |
| Category | Other Medications |
 Status | FDA Approved |
 Estado EMA | med_ema_not_submitted |
 Acceso España | med_spain_not_funded |
| Administration | Oral |
| Year Approved | 2021 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.